Shares for Moderna and Merck experienced a significant rally on Wednesday as investors reacted to successful late-stage clinical data for a collaborative skin cancer treatment. The positive trial outcome has fundamentally shifted the market’s perspective on the commercial viability of personalized mRNA-based therapies.
Moderna’s valuation saw a dramatic increase as share price rose 85% at the open on Wednesday to trade at $116.24 per share. Meanwhile, Merck’s stock also climbed by approximately 7% following the joint update.
The upward momentum was fueled by results from the Phase 3 INTerpath-001 study, which tested a combination of Moderna’s experimental intismeran and Merck’s immunotherapy drug, Keytruda. The companies reported that the trial successfully reached its primary goal, demonstrating a significant extension in the time patients remained free of cancer symptoms following surgery. Furthermore, the therapy showed a distinct advantage in preventing the disease from spreading to other parts of the body when compared to using Keytruda as a standalone treatment.
This personalized mRNA vaccine represents the first treatment of its type to show such clinical benefits for patients with advanced melanoma. Principal researchers highlighted that the drug combination maintained a manageable safety profile, showing superior tolerability compared to certain existing combination therapies used in similar oncology studies. For Merck, the partnership builds on a strong fiscal year, with the company recently reporting second-quarter results that exceeded analyst expectations for both profit and revenue.
Moving forward, the two pharmaceutical giants plan to present their findings to global regulatory bodies to seek official approval. While the companies have not yet confirmed a specific schedule for these filings, the trial success is viewed as a pivotal moment for the future of adjuvant melanoma care.
